Founded in 2015, gene therapy startup MeiraGTx focuses on developing potentially curative treatments for patients living with serious genetic diseases of the central nervous system, eye, and salivary gland. MeiraGTx believes that fine-tuning gene therapy could potentially expand its range to treat non-hereditary diseases such as cancer, diabetes and heart disease. The company has six programmes in clinical development, including one compassionate use programme and a broad pipeline of preclinical and research programmes.
MeiraGTx’s Shannon facility is unique, not only in Ireland but globally, as it streamlines gene therapy development, testing and manufacturing capabilities together in-house. This significantly reduces the time to patients for advanced therapeutic products, with months or potentially years saved.”